Allan James
Research Subjects
Allan James has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Claire Paterson
Beatson West of Scotland Cancer Centre Glasgow UK
5 shared publications - Stefano Schipani
Beatson West Scotland Canc Ctr, Dept Clin Oncol, Glasgow G12 0YN, Scotland
4 shared publications - Christina Wilson
Beatson West Scotland Canc Ctr, Glasgow, Scotland
3 shared publications - Derek Grose
Beatson West of Scotland Cancer Centre, Glasgow, UK
3 shared publications - Adam Peters
Beatson West of Scotland Cancer Centre, Glasgow, UK
2 shared publications - Alekh Thapa
Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
2 shared publications
Latest Publications
- 10 August 2024
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 55 (4) , 101712
How did the COVID-19 pandemic change patient experience during radiation therapy for head and neck cancer: A single centre survey
- 10 August 2024
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 55 (4) , 101712
How did the COVID-19 pandemic change patient experience during radiation therapy for head and neck cancer: A single centre survey
- 12 February 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (5) , 287-299
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland
- 12 February 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (5) , 287-299
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland
- Open Access
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland
Objectives: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma (HNSCC) in the palliative setting in Scotland. Materials and Methods: We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival. Results: Our cohort included 91 patients (median follow-up 10.8 months). Patient characteristics were similar to the KEYNOTE-048 study though our cohort had a higher proportion of patients with newly diagnosed, non-metastatic disease. For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60% (24-month OS had not yet been reached). Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001). Conclusion: Our real-world data support the KEYNOTE-048 study findings and the value of combination treatment options. Additionally, our data show irAEs of any grade, as reported in routine clinical records, are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.
Open AccessThe UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland
Objectives: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma (HNSCC) in the palliative setting in Scotland. Materials and Methods: We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival. Results: Our cohort included 91 patients (median follow-up 10.8 months). Patient characteristics were similar to the KEYNOTE-048 study though our cohort had a higher proportion of patients with newly diagnosed, non-metastatic disease. For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60% (24-month OS had not yet been reached). Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001). Conclusion: Our real-world data support the KEYNOTE-048 study findings and the value of combination treatment options. Additionally, our data show irAEs of any grade, as reported in routine clinical records, are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.
- Open Access
- 26 July 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (7) , omac074
Emergency surgical decompression and long-term survival of glioblastoma presenting in coma in old age: case report and review of prognostic factors
We present a case demonstrating that older age does not exclude long-term survival with glioblastoma. This is a malignant neoplasm with a median life expectancy of 14 months in patients treated with radical intent. Survival is dependent on several independent and interacting prognostic factors of which advancing age is a negative factor. We present a septuagenarian with a 3.5-year survival following aggressive management. The potential to improve glioblastoma survival in an elderly population by examination of additional prognostic factors and identifying biomarkers warrants further research.
- 26 July 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (7) , omac074
Open AccessEmergency surgical decompression and long-term survival of glioblastoma presenting in coma in old age: case report and review of prognostic factors
We present a case demonstrating that older age does not exclude long-term survival with glioblastoma. This is a malignant neoplasm with a median life expectancy of 14 months in patients treated with radical intent. Survival is dependent on several independent and interacting prognostic factors of which advancing age is a negative factor. We present a septuagenarian with a 3.5-year survival following aggressive management. The potential to improve glioblastoma survival in an elderly population by examination of additional prognostic factors and identifying biomarkers warrants further research.
- Open Access
Keep calm and carry on: safety, feasibility and early outcomes of head and neck cancer treatment during the COVID-19 pandemic
Background: Patients with cancer are considered at higher risk of COVID-19 infection and increased severity of infection. Anti-cancer treatment may further increase those risks. The aim of this work is to report early outcomes in patients with head and neck cancer (HNC) treated during the pandemic. Materials and Methods: A retrospective cohort study in a UK tertiary level oncology centre between 1 st March and 23 June 2020, including patients with HNC who were either newly diagnosed, had developed new recurrent/metastatic disease, or were already scheduled to receive treatment during that period. Results: 200 patients were evaluated. Median age was 64 years, 65.5% had multiple co-morbidities, 77.5% were current or ex-smokers and 59.5% lived in areas of deprivation. 99 patients were treated with 6 weeks of radical (chemo) radiotherapy. Systemic anti-cancer treatment was delivered to 40 patients. 2 (1.0%) patients with HNC had confirmed COVID-19 infection; 1 patient prior to primary radical RT - no delay to treatment was required and RT was completed as planned, 1 patient acquired COVID-19 after primary surgery but recovered well and started adjuvant RT 9.7 weeks after surgery. The proportion of patients receiving supportive care only (19.5%) was in keeping with that pre-COVID-19. The proportion of patients not completing (chemo) radiotherapy (3.4%) or with gaps in treatment (14.1%) was similar to pre-COVID-19. 30-day mortality after radical (chemo)radiotherapy was 2.3%, no higher than in previous years. Conclusions: It is feasible and safe to deliver standard treatment for patients with HNC during the COVID-19 pandemic.
Open AccessKeep calm and carry on: safety, feasibility and early outcomes of head and neck cancer treatment during the COVID-19 pandemic
Background: Patients with cancer are considered at higher risk of COVID-19 infection and increased severity of infection. Anti-cancer treatment may further increase those risks. The aim of this work is to report early outcomes in patients with head and neck cancer (HNC) treated during the pandemic. Materials and Methods: A retrospective cohort study in a UK tertiary level oncology centre between 1 st March and 23 June 2020, including patients with HNC who were either newly diagnosed, had developed new recurrent/metastatic disease, or were already scheduled to receive treatment during that period. Results: 200 patients were evaluated. Median age was 64 years, 65.5% had multiple co-morbidities, 77.5% were current or ex-smokers and 59.5% lived in areas of deprivation. 99 patients were treated with 6 weeks of radical (chemo) radiotherapy. Systemic anti-cancer treatment was delivered to 40 patients. 2 (1.0%) patients with HNC had confirmed COVID-19 infection; 1 patient prior to primary radical RT - no delay to treatment was required and RT was completed as planned, 1 patient acquired COVID-19 after primary surgery but recovered well and started adjuvant RT 9.7 weeks after surgery. The proportion of patients receiving supportive care only (19.5%) was in keeping with that pre-COVID-19. The proportion of patients not completing (chemo) radiotherapy (3.4%) or with gaps in treatment (14.1%) was similar to pre-COVID-19. 30-day mortality after radical (chemo)radiotherapy was 2.3%, no higher than in previous years. Conclusions: It is feasible and safe to deliver standard treatment for patients with HNC during the COVID-19 pandemic.
- 1 May 2020
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 58 (4) , 462-468
Postoperative risk stratification in oral squamous cell carcinoma
- 1 May 2020
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 58 (4) , 462-468
Postoperative risk stratification in oral squamous cell carcinoma
- Open Access
- 1 January 2018
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 8, 12-16
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
- 1 January 2018
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 8, 12-16
Open AccessPARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
- Open Access
- 28 May 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 129
The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy
The purpose of this study was to demonstrate how magnetic resonance imaging (MRI) patient position protocols influence registration quality in patients with oropharyngeal cancer undergoing radical radiotherapy and the consequences for gross tumour volume (GTV) definition and radiotherapy planning.
- 28 May 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 129
Open AccessThe influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy
The purpose of this study was to demonstrate how magnetic resonance imaging (MRI) patient position protocols influence registration quality in patients with oropharyngeal cancer undergoing radical radiotherapy and the consequences for gross tumour volume (GTV) definition and radiotherapy planning.